China's medical products administrator approved Guizhou Bailing Group Pharmaceutical (SHE:002424) unit Bailing Yuxiu (Zhuhai) Pharmaceutical's clinical trials for its diabetic retinopathy tablets, according to a Wednesday filing with the Shenzhen Stock Exchange.
The Tangning Tongluo traditional Chinese medicine tablets are indicated for non-proliferative diabetic retinopathy, as well as Yin deficiency, internal heat, and eye network stasis, the report said.
Shares rose 5% during Wednesday's trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments